RespireRx Pharmaceuticals Inc (RSPI)

[gfp927z]

This $2.5 mil financing is a significant development, assuming the financing entity follows through on the subsequent tranches. According to the 8-K they've transacted for $100 K so far. It's possible they might want to see the FDA's response to Cortex/RespireRx's tox data before providing much more funding (?). But if this money is forthcoming it should provide enough funding to get CX-1739 back into the clinic.

Plenty of dilution, and the warrants are each for 2 shares of common stock, but what the heck, at least the company can get things rolling again, and could always do the magical reverse split down the road to get the share count back down to reasonable levels. Either way, Cor/Resp will be way better off than the bio purgatory of past years.

We already know from previous human Phase 2a data that ampakines have excellent efficacy in respiratory depression (CX-717) as well as central sleep apnea (CX-1739), and some activity in mixed sleep apnea. It will also be very interesting to (eventually) see human data for the various orphan breathing related disorders they've been looking at, like Pompe Disease, spinal cord damage, and perinatal respiratory distress.

Ampakine's ability to strongly upregulate the brain's pre-Botz breathing center makes this a platform technology with broad applications, and the orphan indications can be an avenue for accelerated FDA approval. Lucky for us the pre-Botz center of the brain is jam packed with AMPA receptors. Fwiw, I won't use the terms 'multiple shots on goal' or 'slam dunk', no sense jinxing us again, lol..